Aeglea BioTherapeutics to Present Topline Data from Phase 1 Trial of AEB1102 for Treatment of Arginase I Deficiency … – P&T Community

Posted: March 24, 2017 at 12:42 pm

Aeglea BioTherapeutics to Present Topline Data from Phase 1 Trial of AEB1102 for Treatment of Arginase I Deficiency ... P&T Community We are pleased with the data from our Phase 1 study which show that not only was AEB1102 administered safely, but it also rapidly reduced blood arginine levels to the normal range in these patients, said David G. Lowe, Ph.D., chief executive officer ... and more »

View post:
Aeglea BioTherapeutics to Present Topline Data from Phase 1 Trial of AEB1102 for Treatment of Arginase I Deficiency ... - P&T Community